



These additions and changes are effective 10/17/25

Pharmacy Benefit Additions (apply to Exchange only)

- **Romvimza (vimseltinib)**– Pharmacy benefit, Non preferred brand, PA
- **Vykat XR (diazoxide choline)** – Pharmacy benefit, Non preferred brand, PA
- **Qfitlia (fitusiran)** – Pharmacy benefit, Non preferred brand, PA
- **Yeztugo (lenacapavir)**– Pharmacy benefit, Non preferred brand

Pharmacy Benefit Changes (apply to Exchange only)

- **Wakix (pitolisant)** – Pharmacy benefit, Criteria update, New indication excessive daytime sleepiness, adopt Optum criteria
- **Imcivree (setmelanotide)** – Pharmacy benefit, Criteria update, Age update, adopt Optum criteria
- **Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor)** – Pharmacy benefit, Criteria update, expanded age and background table
- **Odactra (Dermatophagoides farinae and Dermatophagoides pteronyssinus)** – Pharmacy benefit, Criteria update, expanded age
- **Vtama (tapinarof)** – Pharmacy benefit, Criteria update, adopt Optum criteria
- **Dupixent (dupilumab)** – Pharmacy benefit, Criteria update, New indication Chronic Spontaneous Urticaria (CSU)
- **Rinvoq (upadacitinib)** – Pharmacy benefit, Criteria update, New indication Giant Cell Arteritis (GCA)

Medical Benefit Additions/Changes (apply to Medicare and Exchange)

- **Qfitlia (fitusiran)** – Medical benefit
- **Zusduri (mitomycin)** – Medical benefit, PA
- **Yeztugo (lenacapavir)** – Medical benefit
- **Emrelis (telisotuzumab vedotin-tllv)** – Medical benefit, PA, Medical Drug Wastage program